Clinical features and common complications of AYA patients with ALL
| Features . | Complications . |
|---|---|
| Treatment toxicity | Steroid-induced hyperglycemia, avascular necrosis |
| Asparginase-induced fatigue, weakness, pancreatitis, thrombosis | |
| Liver dysfunction | |
| Cytogenetic abnormalities | Increased prevalence of high-risk features |
| Ph+ ALL (BCR-ABL1) | |
| iAMP21 | |
| MLL rearrangements | |
| Decreased prevalence of lower-risk features | |
| High hyperdiploidy and/or trisomies of chromosomes 4 and 10 | |
| ETV6-RUNX1 | |
| Social | Poor medical compliance |
| Underinsured | |
| Low enrollment in clinical trials |
| Features . | Complications . |
|---|---|
| Treatment toxicity | Steroid-induced hyperglycemia, avascular necrosis |
| Asparginase-induced fatigue, weakness, pancreatitis, thrombosis | |
| Liver dysfunction | |
| Cytogenetic abnormalities | Increased prevalence of high-risk features |
| Ph+ ALL (BCR-ABL1) | |
| iAMP21 | |
| MLL rearrangements | |
| Decreased prevalence of lower-risk features | |
| High hyperdiploidy and/or trisomies of chromosomes 4 and 10 | |
| ETV6-RUNX1 | |
| Social | Poor medical compliance |
| Underinsured | |
| Low enrollment in clinical trials |
AYA indicates adolescent and young adult; and ALL, acute lymphoblastic leukemia.